Physician profile
Anna H Wallace
NPI 1902030372
$779.37
in general payments reported to CMS, 2019-2025
10 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.64 · 2023: $114 · 2024: $352 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $324.15 | 2019-2025 | Libtayo |
| Stryker Corporation | $167.57 | 2024 | Mako |
| Merck Sharp & Dohme LLC | $139.55 | 2023-2025 | Keytruda, Keytruda Qlex |
| Acera Surgical, INC. | $38.63 | 2025 | Restrata Wound Matrix |
| Radius Health, INC. | $22.79 | 2024 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $20.11 | 2025 | Dysport |
| Iovance Biotherapeutics, INC. | $18.60 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $17.89 | 2025 | Qinlock, Romvimza |
| Vertex Pharmaceuticals Incorporated | $17.50 | 2025 | |
| Array Biopharma INC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.